Pioneering the Next Generation of CAR-T Cell Therapies Gracell is developing cell therapy with the goal of delivering fast, deep and durable responses for people living with cancer and autoimmune disease Learn More Our Mission We are a global clinical-stage biopharmaceutical company dedicated to disco...
Next Generation CAR-T Technology CAR-T cell therapies for blood cancers and solid tumors are being developed by our own significant internal R&D team, based on our comprehensive experience in gene editing, cell therapy and immunotherapy. Advanced, Clinical Stage CAR-T Platform ...
Next Generation CAR-T Technology CAR-T cell therapies for blood cancers and solid tumors are being developed by our own significant internal R&D team, based on our comprehensive experience in gene editing, cell therapy and immunotherapy. Advanced, Clinical Stage CAR-T Platform ...
The next-generation of immune cell therapies requires a new generation of cell analysis tools. Agilent is dedicated to supporting all phases of immune and CAR T cell therapy development with key technologies to enable high-efficiency gene editing and ass
What learnings can we glean from the first-generation T cell therapies, and how can we apply them to next-generation CARs, TILs and TCRs? What new cell types and MOAs are being targeted? What new platforms, delivery systems, and engineering strategies are being developed? Join our speakers...
Chimeric antigen receptor (CAR)-T cell therapies are becoming established as an important treatment modality for cancer. Following the pioneering approval of the CD19-targeted CAR-T therapy tisagenlecleucel by the FDA in 2017, five additional CAR-T therapies have been approved (Supplementary Fig....
Fighting cancer demands an arsenal of therapeutic approaches. That’s why we’re engineering medicines that leverage a diverse array of modalities, including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and CAR T-cell therapies. Discover what we have...
T cells during manufacturing. The acquisition of ImmPACT is expected to significantly strengthen Lyell’s clinical-stage pipeline of next- generation CAR T-cell therapies and complement its suite of proprietary technologies designed to generate longer-lasting, functional T cells to achieve m...
The insights derived from the multidimensional omics data of TIME allow for a comprehensive understanding for tumor immunology, which is critical for the development of next-generation CAR-T cell therapies. Specifically, the multi-omics approach enables the identification of novel biomarkers for patient...
View original content to download multimedia:https://www.prnewswire.com/news-releases/turn-biotechnologies-to-present-at-next-generation-car--t-cell-therapies-conference-on-february-28-301757908.html SOURCE Turn Biotechnologies Twitter LinkedIn